Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 8/20 | 0.53 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.51 |
| ▸ | BCHE | P06276 | 3/20 | 0.50 |
| ▸ | LCK | P06239 | 1/20 | 0.50 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.50 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.50 |
| ▸ | MAOA | P21397 | 1/20 | 0.49 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.49 |
| ▸ | MIF | P14174 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1333722 | 0.84 | MAOB (0.56) | MAOBALOX5BCHECYP4F2CYP4A11 | |
| SCHEMBL1022419 | 0.83 | CYP1A2 (0.56) | MAOBALOX5BCHEMAOANR4A2 | |
| SCHEMBL13667836 | 0.82 | MAOB (0.57) | MAOBALOX5BCHELCKCYP4F2 | |
| SCHEMBL15902884 | 0.82 | MRGPRX4 (0.46) | MAOBALOX5BCHEMAOAMIF | |
| SCHEMBL23838435 | 0.79 | MAOB (0.57) | MAOBALOX5BCHELCKCYP4F2 | |
| SCHEMBL3085833 | 0.79 | CYP3A4 (0.49) | MIFLMNACYP1A2CYP2C19 | |
| SCHEMBL2893673 | 0.78 | MIF (0.57) | MAOBMAOAMIF | |
| SCHEMBL1268719 | 0.77 | MAOB (0.81) | MAOBALOX5BCHELCKCYP4F2 | |
| SCHEMBL13913434 | 0.76 | MAOB (0.50) | MAOBALOX5BCHELCKCYP4F2 | |
| SCHEMBL9301346 | 0.76 | CYSLTR1 (0.60) | ALOX5CYP1A2CYP2C19HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4701635-A1 | 1,2,4-TRIAZOLE-3-THIONE INHIBITORS OF TREX2 FOR USE IN THE TREATMENT OF PSORIASIS, ATOPIC DERMATITIS OR ICHTHYOSIS | Universitat De Barcelona (ES) | 2026-03-04 | — | — | EP | disclosed |
| WO-2024223907-A1 | 1,2,4-TRIAZOLE-3-THIONE INHIBITORS OF TREX2 FOR USE IN THE TREATMENT OF PSORIASIS, ATOPIC DERMATITIS OR ICHTHYOSIS | UNIVERSITAT DE BARCELONA (ES) | 2024-10-31 | — | — | WO | disclosed |
| CN-114540846-B | Synthesis method of 1,2, 4-triazolo six-membered nitrogen heterocycle-3-amine | 五邑大学 | 2023-09-19 | — | — | CN | disclosed |
| CN-114540846-A | Synthetic method of 1,2, 4-triazolo hexa-nitrogen heterocyclic-3-amine | 五邑大学 | 2022-05-27 | — | — | CN | disclosed |
| EP-2035417-B1 | BENZIMIDAZOLES AND THEIR USE FOR THE TREATEMNT OF DIABETES | ASTRAZENECA AB (SE) | 2011-03-02 | — | — | EP | disclosed |
| US-7718671-B2 | Substituted arylthiourea derivatives useful as inhibitors of viral replication | ACHILLION PHARMACEUTICALS, INC. (US) | 2010-05-18 | — | — | US | disclosed |
| US-20090270372-A1 | NOVEL DERIVATIVES OF BENZIMIDAZOLE AND IMIDAZO-PYRIDINE AND THEIR USE AS MEDICAMENTS | SOCIETE DE CONSEILS DE RECHERCHES ET (FR) | 2009-10-29 | — | — | US | disclosed |
| EP-2035417-A1 | BENZIMIDAZOLES AND THEIR USE FOR THE TREATEMNT OF DIABETES | AstraZeneca AB (SE) | 2009-03-18 | — | — | EP | disclosed |
| WO-2007141517-A1 | BENZIMIDAZOLES AND THEIR USE FOR THE TREATEMNT OF DIABETES | ASTRAZENECA AB (SE) | 2007-12-13 | — | — | WO | disclosed |
| EP-1648862-A2 | SUBSTITUTED ARYLTHIOUREA DERIVATIVES USEFUL AS INHIBITORS OF VIRAL REPLICATION | Achillion Pharmaceuticals, Inc. (US) | 2006-04-26 | — | — | EP | disclosed |
| US-20050032849-A1 | Substituted arylthiourea derivatives useful as inhibitors of viral replication | ACHILLION PHARMACEUTICALS, INC. | 2005-02-10 | — | — | US | disclosed |
| WO-2005007601-A2 | SUBSTITUTED ARYLTHIOUREA DERIVATIVES USEFUL AS INHIBITORS OF VIRAL REPLICATION | ACHILLION PHARMACEUTICALS, INC. (US) | 2005-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270372-A1 | NOVEL DERIVATIVES OF BENZIMIDAZOLE AND IMIDAZO-PYRIDINE AND THEIR USE AS MEDICAMENTS | MC4R, MC3R, MC1R | MAOB 1367/4885ALOX5 3405/4885BCHE 3334/4885 |
| US-20050032849-A1 | Substituted arylthiourea derivatives useful as inhibitors of viral replication | TPMT, NAT1, GOT1 | MAOB 1380/4885ALOX5 3700/4885BCHE 2692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.